A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms
暂无分享,去创建一个
G. Weiss | D. V. Von Hoff | L. Smith | E. Rowinsky | S. Gerson | L. Hammond | R. Drengler | J. Kuhn | J. Eckardt | E. Campbell | T. Johnson
[1] H. Eyre,et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. P. Wheeler,et al. Duration of inhibition of synthesis of DNA in tumors and host tissues after single doses of nitrosoureas. , 1974, Cancer research.
[3] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[4] N. Gibson,et al. Specific DNA repair mechanisms may protect some human tumor cells from DNA interstrand crosslinking by chloroethylnitrosoureas but not from crosslinking by other anti-tumor alkylating agents. , 1985, Carcinogenesis.
[5] A. Tates,et al. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] E. Newlands,et al. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. , 1996, British Journal of Cancer.
[7] S. Carter,et al. 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. , 1972, European journal of cancer.
[8] B. Durkacz,et al. (ADP-ribose)n participates in DNA excision repair , 1980, Nature.
[9] K. Kohn,et al. Chapter 6 – DNA CROSSLINKING AND THE ORIGIN OF SENSITIVITY TO CHLOROETHYLNITROSOUREAS , 1981 .
[10] T. Kummet. Chemotherapy of sarcomas. , 1983, Arizona medicine.
[11] M. Dolan,et al. O6-benzylguanine and its role in chemotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] N. Curtin,et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. , 1995, British Journal of Cancer.
[13] L. Erickson,et al. Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone. , 1983, Carcinogenesis.
[14] M. Tisdale. Antitumour imidazotetrazines--XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism. , 1985, British Journal of Cancer.
[15] P. Kleihues,et al. Inhibition of the hepatic O6-alkylguanine-DNA alkyltransferase in vivo by pretreatment with antineoplastic agents. , 1989, Biochemical pharmacology.
[16] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[17] M. Dolan,et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. , 1995, Cancer research.
[18] M M Haglund,et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Buckner,et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] M. Dolan,et al. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea , 2004, Cancer Chemotherapy and Pharmacology.
[21] K. Kohn,et al. Binding of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea to L1210 cell nuclear proteins. , 1976, Cancer research.
[22] A. Sancar. Mechanisms of DNA excision repair. , 1994, Science.
[23] M. D’Incalci,et al. Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. , 1988, Cancer treatment reviews.
[24] S. Gerson. Modulation of human lymphocyte O6-alkylguanine-DNA alkyltransferase by streptozotocin in vivo. , 1989, Cancer research.
[25] M. Roddie,et al. Phase I trial of temozolomide using an extended continuous oral schedule. , 1998, Cancer research.
[26] D. Crowther,et al. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. , 1994, British Journal of Cancer.
[27] E. Frei,et al. 1,3 Bis‐(2 chloroethyl)‐1‐nitrosourea and streptozotocin chemotherapy , 1975, Clinical pharmacology and therapeutics.
[28] J. Willson,et al. O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance. , 1995, Hematology/oncology clinics of North America.
[29] M. Dolan,et al. Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. , 1990, Cancer communications.
[30] R. McLendon,et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] P. Kleihues,et al. O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. , 1989, Journal of neurosurgery.
[32] S. Keir,et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. , 1997, Cancer research.
[33] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .
[34] M. Tisdale. Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. , 1987, Biochemical pharmacology.
[35] L. Tentori,et al. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds , 1999, Leukemia.
[36] E. Newlands,et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.
[37] J. Willson,et al. Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine. , 1992, Biochemical pharmacology.
[38] M. Stevens,et al. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. , 1994, Biochemistry.
[39] A. Prestayko. Nitrosoureas : current status and new developments , 1981 .
[40] M R Grever,et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. , 1994, Cancer research.
[41] R. Fisher,et al. Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. , 1992, Journal of the National Cancer Institute.
[42] G. Margison,et al. Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. , 1993, British Journal of Cancer.
[43] E. Winer,et al. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. , 1992, Cancer research.
[44] L. Erickson,et al. Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. , 1984, Carcinogenesis.
[45] K. Kohn,et al. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells , 1980, Nature.
[46] J. Haaga,et al. Modulation of O6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] S P Langdon,et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.
[48] S. Haas,et al. Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue. , 1996, Cancer detection and prevention.
[49] M. Berger,et al. Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. , 1993, Cancer research.
[50] P. Houghton,et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] M. Prados,et al. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. , 2000, Neuro-oncology.
[52] S. Gerson. Regeneration of O6-alkylguanine-DNA alkyltransferase in human lymphocytes after nitrosourea exposure. , 1988, Cancer research.
[53] S. Schold,et al. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[54] D. Farquhar,et al. Mechanism of action and pharmacology studies with DTIC (NSC-45388). , 1976, Cancer treatment reports.
[55] R. Fisher,et al. Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. , 1989, Cancer communications.
[56] J. Haaga,et al. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. , 1999, Cancer research.
[57] J. Edmonson,et al. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. , 1965, Cancer research.
[58] N. Berger,et al. O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells. , 1985, The Journal of clinical investigation.
[59] A. Pegg,et al. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. , 1990, Cancer research.
[60] N. Bleehen,et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] R. Pieper,et al. Effects of streptozotocin/bis-chloroethylnitrosourea combination therapy on O6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro. , 1991, Cancer research.
[62] G. Bonadonna,et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.
[63] S. Gerson,et al. Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase. , 1988, Cancer research.
[64] M. Dolan,et al. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. , 1995, Progress in nucleic acid research and molecular biology.
[65] S. Markowitz,et al. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. , 1996, Cancer research.
[66] E. Newlands,et al. Effect of single and multiple administration of an O 6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model , 1997, Cancer Chemotherapy and Pharmacology.
[67] M. Berger,et al. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. , 1998, Cancer research.
[68] M. Gibaldi. Biopharmaceutics and clinical pharmacokinetics , 1977 .